Fig. 6.

RGS and BRAF/MEK inhibitors induce CD40 expression on melanoma cells and tumors of patients responsive to RAS/RAF/MEK pathway inhibition. a NRAS^mut melanoma PDX 1179 and PDX1214 tumor growth over time in NSG mice with IHC staining of cleaved-caspase3, CD40 and SOX10 in from mice treated with the vehicle or 300 mg/kg rigosertib (RGS). 20X and 40X images and the scale marker are shown. b IHC staining of CD40 and SOX10 in BRAF^mut melanoma PDX tumors from mice treated with the vehicle or Dabrafenib + Trametinib (D + T). c Correlation analysis of T. Ratio and CD40 fold-change post treatment in PDXs shown in b. The T. Ratio, obtained from the statistical analysis of treatment difference comparisons of the tumor growth rate based on the tumor volume, for each PDX treatment comparison. d H&E and multiplex sequential IHC analysis of hematoxylin, CD40, CD80, CD11c, CD8 and SOX10 of patient melanoma sections. Cell number of SOX10⁺CD40⁺ cells was identified of 11 paired tumor sections pre- and post-BRAF inhibitor treatment (paired t-test). Pooled data (n = 4 ~ 11) from one experiment are shown